0.7756
price down icon3.34%   -0.0268
pre-market  Vorhandelsmarkt:  .77   -0.0056   -0.72%
loading
Schlusskurs vom Vortag:
$0.8024
Offen:
$0.7968
24-Stunden-Volumen:
1.22M
Relative Volume:
0.28
Marktkapitalisierung:
$23.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.77M
KGV:
-0.0507
EPS:
-15.2954
Netto-Cashflow:
$-24.23M
1W Leistung:
+23.37%
1M Leistung:
+190.49%
6M Leistung:
-55.68%
1J Leistung:
-80.80%
1-Tages-Spanne:
Value
$0.76
$0.85
1-Wochen-Bereich:
Value
$0.6201
$0.96
52-Wochen-Spanne:
Value
$0.25
$4.07

Moleculin Biotech Inc Stock (MBRX) Company Profile

Name
Firmenname
Moleculin Biotech Inc
Name
Telefon
713-300-5160
Name
Adresse
5300 MEMORIAL DRIVE, HOUSTON, TX
Name
Mitarbeiter
17
Name
Twitter
@moleculinbio
Name
Nächster Verdiensttermin
2024-12-08
Name
Neueste SEC-Einreichungen
Name
MBRX's Discussions on Twitter

Vergleichen Sie MBRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MBRX
Moleculin Biotech Inc
0.7756 18.99M 0 -29.77M -24.23M -15.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-09 Fortgesetzt H.C. Wainwright Buy
2025-02-12 Herabstufung Maxim Group Buy → Hold
2022-07-18 Fortgesetzt Oppenheimer Outperform

Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten

pulisher
Jul 22, 2025

Moleculin Biotech Inc. Stock Analysis and ForecastExponential wealth increase - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Moleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

Moleculin Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times

Jul 22, 2025
pulisher
Jul 22, 2025

Exclusive: Moleculin CEO Shares Vision Behind Revolutionary Cancer Drug Pipeline in New Investor Presentation - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

Is Moleculin Biotech Inc. a good long term investmentSignificant capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Moleculin Biotech Gains Approval for Phase 2B/3 AML Study - MSN

Jul 21, 2025
pulisher
Jul 21, 2025

What drives Moleculin Biotech Inc. stock priceAccelerated earnings growth - Autocar Professional

Jul 21, 2025
pulisher
Jul 20, 2025

What analysts say about Moleculin Biotech Inc. stockMassive wealth growth - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 18, 2025

Moleculin Biotech Appoints Adriano Treve as Strategic Advisor - The Globe and Mail

Jul 18, 2025
pulisher
Jul 17, 2025

Moleculin appoints former Roche executive as strategic advisor - Investing.com Australia

Jul 17, 2025
pulisher
Jul 17, 2025

Moleculin appoints former Roche executive as strategic advisor By Investing.com - Investing.com Canada

Jul 17, 2025
pulisher
Jul 17, 2025

Moleculin Biotech, Inc. Appoints Adriano Treve as Strategic Advisor to Enhance Partnerships and Advance Clinical Trials - Nasdaq

Jul 17, 2025
pulisher
Jul 17, 2025

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships - GlobeNewswire

Jul 17, 2025
pulisher
Jul 15, 2025

What makes Moleculin Biotech Inc. stock price move sharplySmart Trading With Safety Margin - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Moleculin Biotech Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Moleculin Biotech Surges 19.5%—What's Fueling the Rally? - AInvest

Jul 14, 2025
pulisher
Jul 11, 2025

Moleculin Biotech enters $6.5 million at-the-market equity offering agreement By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 11, 2025

Moleculin Biotech Enters New Stock Offering Agreement - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

Moleculin Biotech enters $6.5 million at-the-market equity offering agreement - Investing.com

Jul 11, 2025
pulisher
Jul 10, 2025

Moleculin Acquires $2M Private Grant for Brain Tumor Trial at MD Anderson - BioTecNika

Jul 10, 2025
pulisher
Jul 10, 2025

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans - GlobeNewswire

Jul 10, 2025
pulisher
Jul 09, 2025

Moleculin receives Georgian approval for pivotal AML treatment trial By Investing.com - Investing.com India

Jul 09, 2025
pulisher
Jul 09, 2025

Moleculin receives Georgian approval for pivotal AML treatment trial - Investing.com Australia

Jul 09, 2025
pulisher
Jul 09, 2025

Moleculin Biotech Stock Soars 13.44% on Clinical Trial Expansion - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Moleculin Biotech, Inc. Secures RAMPA Approval for Phase 2B/3 MIRACLE Trial in Georgia, Expanding Clinical Recruitment Efforts - Nasdaq

Jul 09, 2025
pulisher
Jul 09, 2025

MBRX gains RAMPA nod for pivotal Phase 2B/3 AnnAraC AML trial | THTX SEC FilingForm 6-K - Stock Titan

Jul 09, 2025
pulisher
Jul 09, 2025

Moleculin's Phase 3 AML Treatment Trial Gains Momentum: 7 Patients Treated, 16 New Sites Coming - Stock Titan

Jul 09, 2025
pulisher
Jul 03, 2025

Favourable Signals For Moleculin Biotech: Numerous Insiders Acquired Stock - simplywall.st

Jul 03, 2025
pulisher
Jul 03, 2025

Several Insiders Invested In Moleculin Biotech Flagging Positive News - Yahoo Finance

Jul 03, 2025
pulisher
Jun 27, 2025

Moleculin Biotech (MBRX) Price Target Reduced to $13 by Roth Cap - GuruFocus

Jun 27, 2025
pulisher
Jun 27, 2025

Moleculin Biotech Faces Nasdaq Delisting Warning - TipRanks

Jun 27, 2025
pulisher
Jun 26, 2025

Healthcare Stocks to Watch: Catalyst Pharmaceuticals, AVITA Medical, and Moleculin Biotech. - AInvest

Jun 26, 2025
pulisher
Jun 23, 2025

Moleculin Biotech Raises $5.9M in Public Offering - TipRanks

Jun 23, 2025
pulisher
Jun 21, 2025

Health Care Stocks Stumble Amid Market Adjustments - Finimize

Jun 21, 2025
pulisher
Jun 21, 2025

Moleculin Biotech's $5.9M Financing: A Lifeline for Annamycin or a Risky Gamble? - AInvest

Jun 21, 2025
pulisher
Jun 20, 2025

Moleculin Biotech prices $5.9M public offering; shares down about 47% - MSN

Jun 20, 2025
pulisher
Jun 20, 2025

Moleculin Biotech's 48% Plunge: Technical Sell-Off or Sector Sentiment Shift? - AInvest

Jun 20, 2025
pulisher
Jun 19, 2025

Moleculin Biotech (NASDAQ:MBRX) Given Buy Rating at HC Wainwright - Defense World

Jun 19, 2025
pulisher
Jun 18, 2025

Moleculin Biotech (MBRX) Rating Reiterated with $4.00 Price Target | MBRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML - GlobeNewswire

Jun 18, 2025
pulisher
Jun 18, 2025

Moleculin Participates in Virtual Investor “What This Means” Seg - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Moleculin Biotech’s Annamycin Pediatric Study Approved by FDA - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Moleculin Participates in Virtual Investor “What This Means” Segment - GlobeNewswire

Jun 18, 2025

Finanzdaten der Moleculin Biotech Inc-Aktie (MBRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):